The Application of Sodium-Glucose Cotransporter 2 Inhibitors to Chronic Kidney Disease Stage 4.

about

Sodium-Glucose Cotransporter 2 Inhibitors Reduce Prandial Insulin Doses in Type 2 Diabetic Patients Treated With the Intensive Insulin Therapy.

P2860

Q55513324-2F50DD13-03A3-42D1-B72F-146E7C68E9FF

P2860

The Application of Sodium-Glucose Cotransporter 2 Inhibitors to Chronic Kidney Disease Stage 4.

Item

http://www.wikidata.org/entity/Q47110037

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

The Application of Sodium-Gluc ...... hronic Kidney Disease Stage 4.

@en

The Application of Sodium-Gluc ...... hronic Kidney Disease Stage 4.

@nl

type

Item

label

The Application of Sodium-Gluc ...... hronic Kidney Disease Stage 4.

@en

The Application of Sodium-Gluc ...... hronic Kidney Disease Stage 4.

@nl

prefLabel

The Application of Sodium-Gluc ...... hronic Kidney Disease Stage 4.

@en

The Application of Sodium-Gluc ...... hronic Kidney Disease Stage 4.

@nl

P1476

The Application of Sodium-Gluc ...... hronic Kidney Disease Stage 4.

@en

P2093

Ayako Koguchi

http://www.w3.org/2001/XMLSchema#string

Hidekatsu Yanai

http://www.w3.org/2001/XMLSchema#string

Hiroki Adachi

http://www.w3.org/2001/XMLSchema#string

P2860

Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering

Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline Data

SGLT2 mediates glucose reabsorption in the early proximal tubule.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters in Patients With Type 2 Diabetes: A Chart-Based Analysis.

An Influence of the Estimated Glomerular Filtration Rate on Improvement in Metabolic Parameters by Sodium-Glucose Cotransporter 2 Inhibitors.

Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes.

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.

P304

1029-1031

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.14740/JOCMR3220W

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29163740

http://www.w3.org/2001/XMLSchema#string

P932

5687911

http://www.w3.org/2001/XMLSchema#string

The Application of Sodium-Glucose Cotransporter 2 Inhibitors to Chronic Kidney Disease Stage 4.

about

P2860

P2860

The Application of Sodium-Glucose Cotransporter 2 Inhibitors to Chronic Kidney Disease Stage 4.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932